749 related articles for article (PubMed ID: 16286363)
1. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
2. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
7. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
Bick RL
J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
[TBL] [Abstract][Full Text] [Related]
9. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
Lopez LM
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):56S-61S; discussion 71S-72S. PubMed ID: 11401194
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
Dranitsaris G; Shane LG; Woodruff S
J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
[TBL] [Abstract][Full Text] [Related]
13. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
14. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
15. Update in the treatment of venous thromboembolism.
Garcia DA; Spyropoulos AC
Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
17. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
[TBL] [Abstract][Full Text] [Related]
18. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.
Nutescu EA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S5-13. PubMed ID: 17519445
[TBL] [Abstract][Full Text] [Related]
19. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
